Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus.

Literature DB >> 11574616

Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus.

H Watanabe¹, H Masaki, N Asoh, K Watanabe, K Oishi, S Kobayashi, A Sato, R Sugita, T Nagatake.

Abstract

We describe a patient with methicillin-resistant Staphylococcus aureus (MRSA) colonizing the pharynx. The MIC of mupirocin was 0.25 microg/ml before treatment and increased after treatment to 8 microg/ml. Using pulsed-field gel electrophoresis, we confirmed that the genotypes of MRSA that colonized the pharynx before and after the use of mupirocin were identical. We measured the delivery of mupirocin to the pharynx in three normal volunteers and two patients. Low concentrations of mupirocin were present in the pharynx in all cases 10 min to 3 days after intranasal application. Our data suggested that low concentrations of the drug in the pharynx after intranasal application of mupirocin ointment might explain the selection of mupirocin resistance in MRSA.

Entities: Chemical Species

Mesh：

Substances：

Year: 2001 PMID： 11574616 PMCID： PMC88432 DOI： 10.1128/JCM.39.10.3775-3777.2001

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

16 in total

1. MRSA meningitis in postoperative patients. Report of 4 cases.

Authors: T Sakamoto; K Kikuchi; K Mineura; M Kowada; O Nakagomi
Journal: Jpn J Antibiot Date: 1990-06

2. The use of mupirocin in controlling methicillin-resistant Staphylococcus aureus.

Authors: H C Neu
Journal: Infect Control Hosp Epidemiol Date: 1990-01 Impact factor: 3.254

3. Mupirocin-resistant Staphylococcus aureus.

Authors: B D Cookson; R W Lacey; W C Noble; D S Reeves; R Wise; R J Redhead
Journal: Lancet Date: 1990-05-05 Impact factor: 79.321

4. Staphylococcus aureus resistant to mupirocin.

Authors: G E Smith; C T Kennedy
Journal: J Antimicrob Chemother Date: 1988-01 Impact factor: 5.790

5. Methicillin-resistant Staphylococcus aureus as a causative agent of postoperative intra-abdominal infection: relation to nasal colonization.

Authors: L Fierobe; D Decré; C Mùller; J C Lucet; J P Marmuse; J Mantz; J M Desmonts
Journal: Clin Infect Dis Date: 1999-11 Impact factor: 9.079

6. Molecular analysis of methicillin-resistant Staphylococcus aureus as a causative agent of bronchopulmonary infection: relation to colonization in the upper respiratory tract.

Authors: H Watanabe; H Masaki; N Asoh; K Watanabe; K Oishi; S Kobayashi; A Sato; T Nagatake
Journal: J Clin Microbiol Date: 2000-10 Impact factor: 5.948

7. Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures.

Authors: R P Wenzel; M D Nettleman; R N Jones; M A Pfaller
Journal: Am J Med Date: 1991-09-16 Impact factor: 4.965

8. High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases.

Authors: J Gilbart; C R Perry; B Slocombe
Journal: Antimicrob Agents Chemother Date: 1993-01 Impact factor: 5.191

9. Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak.

Authors: R L Hill; G J Duckworth; M W Casewell
Journal: J Antimicrob Chemother Date: 1988-09 Impact factor: 5.790

10. Nasal carriage of Staphylococcus aureus and cross-contamination in a surgical intensive care unit: efficacy of mupirocin ointment.

Authors: D Talon; C Rouget; V Cailleaux; P Bailly; M Thouverez; F Barale; Y Michel-Briand
Journal: J Hosp Infect Date: 1995-05 Impact factor: 3.926

15 in total

1. Molecular characterization of resistance to mupirocin in methicillin-susceptible and -resistant isolates of Staphylococcus aureus from nasal samples.

Authors: Fernando Chaves; Jesus García-Martínez; Sonia de Miguel; Joaquín R Otero
Journal: J Clin Microbiol Date: 2004-02 Impact factor: 5.948

Review 2. Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents.

Authors: Julian Gregston Hurdle; Alexander John O'Neill; Ian Chopra
Journal: Antimicrob Agents Chemother Date: 2005-12 Impact factor: 5.191

3. Mupirocin-induced mutations in ileS in various genetic backgrounds of methicillin-resistant Staphylococcus aureus.

Authors: Andie S Lee; Yann Gizard; Joanna Empel; Eve-Julie Bonetti; Stephan Harbarth; Patrice François
Journal: J Clin Microbiol Date: 2014-08-13 Impact factor: 5.948

4. Antibacterial activity of REP8839, a new antibiotic for topical use.

Authors: Ian A Critchley; Casey L Young; Kimberley C Stone; Urs A Ochsner; Joseph Guiles; Ted Tarasow; Nebojsa Janjic
Journal: Antimicrob Agents Chemother Date: 2005-10 Impact factor: 5.191

5. Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase.

Authors: Urs A Ochsner; Casey L Young; Kimberley C Stone; Frank B Dean; Nebojsa Janjic; Ian A Critchley
Journal: Antimicrob Agents Chemother Date: 2005-10 Impact factor: 5.191

6. In vitro and in vivo evaluations of the activities of lauric acid monoester formulations against Staphylococcus aureus.

Authors: Mark S Rouse; Margalida Rotger; Kerryl E Piper; James M Steckelberg; Matthew Scholz; Jeffrey Andrews; Robin Patel
Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191

10. Efficacy of skin and nasal povidone-iodine preparation against mupirocin-resistant methicillin-resistant Staphylococcus aureus and S. aureus within the anterior nares.

Authors: Michele J Anderson; Maren L David; Matt Scholz; Sally J Bull; Dan Morse; Michelle Hulse-Stevens; Marnie L Peterson
Journal: Antimicrob Agents Chemother Date: 2015-03-02 Impact factor: 5.191